Soysouvanh Frédéric, Giuliano Serena, Habel Nadia, El-Hachem Najla, Pisibon Céline, Bertolotto Corine, Ballotti Robert
Inserm U1065, C3M, Team 1, Biology, and Pathologies of Melanocytes, University of Nice Côte d'Azur, 06200 Nice, France.
Laboratory of Cancer Signaling, University of Liège, 4020 Liège, Belgium.
J Clin Med. 2021 Mar 8;10(5):1133. doi: 10.3390/jcm10051133.
The ubiquitination system plays a critical role in regulation of large array of biological processes and its alteration has been involved in the pathogenesis of cancers, among them cutaneous melanoma, which is responsible for the most deaths from skin cancers. Over the last decades, targeted therapies and immunotherapies became the standard therapeutic strategies for advanced melanomas. However, despite these breakthroughs, the prognosis of metastatic melanoma patients remains unoptimistic, mainly due to intrinsic or acquired resistances. Many avenues of research have been investigated to find new therapeutic targets for improving patient outcomes. Because of the pleiotropic functions of ubiquitination, and because each step of ubiquitination is amenable to pharmacological targeting, much attention has been paid to the role of this process in melanoma development and resistance to therapies. In this review, we summarize the latest data on ubiquitination and discuss the possible impacts on melanoma treatments.
泛素化系统在大量生物过程的调控中发挥着关键作用,其改变与癌症的发病机制有关,其中包括皮肤黑色素瘤,它是导致皮肤癌死亡人数最多的癌症。在过去几十年中,靶向治疗和免疫治疗已成为晚期黑色素瘤的标准治疗策略。然而,尽管有这些突破,转移性黑色素瘤患者的预后仍然不容乐观,主要是由于内在或获得性耐药。为了找到改善患者预后的新治疗靶点,人们已经研究了许多研究途径。由于泛素化具有多效性功能,并且泛素化的每个步骤都适合进行药物靶向,因此该过程在黑色素瘤发展和治疗耐药中的作用受到了广泛关注。在这篇综述中,我们总结了关于泛素化的最新数据,并讨论了其对黑色素瘤治疗的可能影响。